Biomarkers in Routine Heart Failure Clinical Care

Nadar, Sunil; Shaikh, Mohammad Mujtaba

doi:10.15420/cfr.2018.27.2

Cited by 93 publications

(90 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown elevation of cardiac injury markers and acute phase proteins are indicators of cardiovascular events associated with influenza virus infection (38,39). Myocardial injury can be determined by serum biomarkers including the MB form of creatine kinase (CK-MB), lactate dehydrogenase (LDH), and troponin (TnT) (40,41). Cardiac injury markers are shown to be elevated in influenza-positive veterans within 30 days of laboratory confirmation (42).…”

Section: Association Between Influenza Virus Infection and Cardiovascmentioning

confidence: 99%

“…Acute phase proteins are also potential biomarkers for cardiovascular diseases. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are the biomarkers in diagnosis of heart failure (40,41). Increased levels of C-reactive protein (CRP) and NT-proBNP, along with increased leukocyte numbers, correlated with mortality rate in elderly patients with 2009 H1N1 infections and cardiovascular diseases (43).…”

Section: Association Between Influenza Virus Infection and Cardiovascmentioning

confidence: 99%

See 1 more Smart Citation

Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection

2020

View full text Add to dashboard Cite

Influenza virus infection causes 3-5 million cases of severe illness and 250,000-500,000 deaths worldwide annually. Although pneumonia is the most common complication associated with influenza, there are several reports demonstrating increased risk for cardiovascular diseases. Several clinical case reports, as well as both prospective and retrospective studies, have shown that influenza can trigger cardiovascular events including myocardial infarction (MI), myocarditis, ventricular arrhythmia, and heart failure. A recent study has demonstrated that influenza-infected patients are at highest risk of having MI during the first seven days of diagnosis. Influenza virus infection induces a variety of pro-inflammatory cytokines and chemokines and recruitment of immune cells as part of the host immune response. Understanding the cellular and molecular mechanisms involved in influenza-associated cardiovascular diseases will help to improve treatment plans. This review discusses the direct and indirect effects of influenza virus infection on triggering cardiovascular events. Further, we discussed the similarities and differences in epidemiological and pathogenic mechanisms involved in cardiovascular events associated with coronavirus disease 2019 (COVID-19) compared to influenza infection.

show abstract

Section: Association Between Influenza Virus Infection and Cardiovascmentioning

confidence: 99%

Section: Association Between Influenza Virus Infection and Cardiovascmentioning

confidence: 99%

Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection

2020

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6] Nevertheless, with the growing complexity and heterogeneity observed in HF progression, delineation of more reliable biomarkers with higher specificity and sensitivity for the early diagnosis and molecular monitoring of the disease state, and for having an accurate expectation of prognosis with sufficiently predictive precision is still urgent to optimize treatment options and decline mortality. 7 Besides high sensitivity and specificity, the ideal and implementable biomarker must meet several key criteria. It needs to be readily accessible; a biomarker must be ideally detected in easily reachable body fluids, such as plasma/serum, saliva, and urine.…”

Section: Introductionmentioning

confidence: 99%

Circulating exosomal microRNAs as emerging non‐invasive clinical biomarkers in heart failure: Mega bio‐roles of a nano bio‐particle

et al. 2020

View full text Add to dashboard Cite

Exosomes are nano-sized extracellular vesicles containing a cell-specific biologically active cargo of proteins and genetic materials. Exosomes are constitutively released from almost all cell-types and affect neighboring or distant cells through a complex intercellular exchange of the genetic information and/or regulation of certain gene expressions that change the function and behavior of recipient cells. Those released into body fluids are the major mediators of intercellular communications. The success of the biological functions of exosomes is highly mediated by the effective transfer of microRNAs (miRs). Exosomes secreted by a damaged or diseased heart can exhibit alterations in the miRs' profile that may reflect the cellular origin and (patho)physiological state, as a "signature" or "fingerprint" of the donor cell. It has been shown that the transportation of cardiac-specific miRs in exosomes can be rapidly detected and measured, holding great potential as biomarkers in heart diseases. Currently, the search for new biomarkers of heart diseases remains a large and increasing enterprise. Notably, circulating exosomal miRs (Exo-miRs) have successfully gained huge interests for their diagnostic and prognostic potentials. The present review highlights circulating Exo-miRs explored for diagnosis/prognosis and outcome prediction in patients with heart failure (HF). To this end, we explain the feasibility of exosomes as clinical biomarkers, discuss the priority of circulating Exo-miRs over non-exosomal ones as a biomarker, and then outline reported circulating Exo-miRs having the biomarker function in HF patients, together with their mechanism of action. In conclusion, circulating Exo-miRs represent emerging diagnostic (Exo-miR-92b-5p, Exo-miR-146a, Exo-miR-181c, and Exo-miR-495) and prognostic (Exo-miR-192, Exo-miR-194, Exo-miR-34a, Exo-miR-425, Exo-miR-744) biomarkers for HF.

show abstract

“…The importance of studying cardiac biomarkers in the diagnosis and prognostic stratification of children with HF has been well emphasized; these biomarkers may act as future therapeutic targets (7). Similarly, noninvasive tools to monitor patients with HF before the occurrence of clinical deterioration are also required (8).…”

Section: Introductionmentioning

confidence: 99%

Matrix metalloproteinase‑9 in pediatric rheumatic heart disease with and without heart failure

et al. 2020

View full text Add to dashboard Cite

In cardiovascular disorders, the myocardium may be subjected to the breakdown and remodeling of collagen by metalloproteinase-9 (MMP-9). We hypothesized that the serum MMP-9 concentration may be elevated in pediatric patients with rheumatic heart disease (RHD) and heart failure (HF), and its level can be correlated with the HF severity. Thus, in the present study, we aimed to evaluate the sensitivity and accuracy of MMP-9 to predict HF in children with RHD and to determine its effectiveness as an indicator of the degree of HF. This study included 98 consecutive children admitted to the

show abstract

Biomarkers in Routine Heart Failure Clinical Care

Cited by 93 publications

References 74 publications

Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection

Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection

Circulating exosomal microRNAs as emerging non‐invasive clinical biomarkers in heart failure: Mega bio‐roles of a nano bio‐particle

Matrix metalloproteinase‑9 in pediatric rheumatic heart disease with and without heart failure

Contact Info

Product

Resources

About